Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Soluble guanylate cyclases are heterodimeric proteins that catalyze the conversion of GTP to 3',5'-cyclic GMP and pyrophosphate. Additionally we are shipping GUCY1A2 Proteins (3) and GUCY1A2 Kits (1) and many more products for this protein.
Showing 10 out of 16 products:
Human Polyclonal GUCY1A2 Primary Antibody for EIA, IHC (p) - ABIN360707
Baba, Suzuki, Arai, Emson: Expression of nNOS and soluble guanylate cyclase in schizophrenic brain. in Neuroreport 2004
Show all 3 references for 360707
Human Polyclonal GUCY1A2 Primary Antibody for EIA, WB - ABIN493444
Wedel, Garbers: Guanylyl cyclases: approaching year thirty. in Trends in endocrinology and metabolism: TEM 2008
Show all 3 references for 493444
Human Polyclonal GUCY1A2 Primary Antibody for EIA, WB - ABIN493442
Kobiałka, Gorczyca: Particulate guanylyl cyclases: multiple mechanisms of activation. in Acta biochimica Polonica 2001
Show all 3 references for 493442
Human Polyclonal GUCY1A2 Primary Antibody for EIA, IHC (p) - ABIN359276
Bellamy, Wood, Garthwaite: On the activation of soluble guanylyl cyclase by nitric oxide. in Proceedings of the National Academy of Sciences of the United States of America 2002
Show all 3 references for 359276
These data suggests a novel physiological role for PDE5 (show PDE5A Antibodies) in restricting the effects of NOS3 (show NOS3 Antibodies)/sGC (show NPR1 Antibodies)/PKG (show PRKG1 Antibodies) signaling pathway to modulating beta-AR stimulated I(Ca), while limiting effects on cardiac contraction.[sGC (show NPR1 Antibodies)]
Requirement of both alpha-2 and alpha-1 guanylate cyclases for signaling in long-term potentiation (LTP (show SCP2 Antibodies)) indicates the existence of two distinct nitric oxide/cGMP-mediated pathways, which have to work in concert for expression of LTP (show SCP2 Antibodies).
The aim of this study was to investigate the role of Gucy1a2 in nitrergic regulation of gastric motility in male and female Gucy1a2 knock-out mice.
The data support a novel regulatory mechanism whereby sGC (show SGCB Antibodies) activity is tuned by distinct domain interactions that either promote or inhibit catalytic activity.
The CO binding affinity of soluble guanylate cyclase alpha 2 subunit is threefold greater than that of human soluble guanylate cyclase alpha 1 subunit.
The sGC (show SGCB Antibodies) alpha 1observed in OVCAR-3 and MDA-MB-468 cancer cells which correlated well with the sGC (show SGCB Antibodies) activity and a marked increase in cGMP levels upon exposure to the combination of a NO donor and a sGC (show SGCB Antibodies) activator.
Soluble guanylyl cyclase (sGC (show SGCB Antibodies)) is the major cellular receptor for the intercellular messenger nitric oxide (NO) and mediates a wide range of physiological effects through elevation of intracellular cGMP levels
No significant changes were found in sGC (show SGCB Antibodies) subunit mRNAs in people with schizophrenia or in controls.
Soluble guanylate cyclases are heterodimeric proteins that catalyze the conversion of GTP to 3',5'-cyclic GMP and pyrophosphate. The protein encoded by this gene is an alpha subunit of this complex and it interacts with a beta subunit to form the guanylate cyclase enzyme, which is activated by nitric oxide. Two transcript variants encoding different isoforms have been found for this gene.
guanylate cyclase 1, soluble, alpha 2
, guanylate cyclase soluble subunit alpha-2
, guanylate cyclase soluble subunit alpha-2-like
, soluble guanylyl cyclase alpha2 subunit